comparemela.com

Page 35 - ரோச் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Novartis canakinumab failed to improve survival in COVID-19 study

Novartis’ canakinumab failed to improve survival in COVID-19 study Swiss pharma company had been studying drug in hospitalised COVID-19 patients Novartis’ arthritis drug canakinumab failed to hit its primary endpoint of improving survival for COVID-19 patients without the need for invasive mechanical ventilation, the Swiss pharma company announced today. Novartis had been studying the drug in hospitalised patients with COVID-19 pneumonia and cytokine release syndrome (CRS). The trial failed to show that treatment with canakinumab plus standard of care demonstrated a significantly greater chance of survival for patients without the need for invasive mechanical ventilation, compared with standard of care at day 29.

Roche s Covid antibody cocktail launched at Rs 59,750/dose for treatment of mild to moderate patients

URL copied Roche s Covid antibody cocktail launched in India for treatment of mild to moderate cases Drug majors Roche India and Cipla on Monday announced launch of Roche s Antibody Cocktail in India priced at Rs 59,750 per dose for the treatment of mild to moderate COVID-19 in patients who are at high risk. The first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients, Cipla and Roche said in a joint statement.

Roche s antibody cocktail launched in India at ₹59,750/dose - The Hindu BusinessLine

Roche’s antibody cocktail launched in India at ₹59,750/dose PTI New Delhi | Updated on May 24, 2021 Cipla to market drug in country Drug majors Roche India and Cipla on Monday announced launch of Roche s Antibody Cocktail in India priced at ₹59,750 per dose for the treatment of mild to moderate Covid-19 in patients who are at high risk. “The first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients, Cipla and Roche said in a joint statement. Cipla will distribute the product by leveraging its strong distribution strengths across the country, it added.

Covid: Roche s antibody cocktail launched in India, Cipla to market drug

UPDATED: May 24, 2021 13:51 IST The drug will be available through leading hospitals and Covid treatment centers. (Photo: PTI/ for Representation) Drug majors Roche India and Cipla on Monday announced launch of Roche s Antibody Cocktail in India priced at Rs 59,750 per dose for the treatment of mild to moderate Covid-19 in patients who are at high risk. The first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients, Cipla and Roche said in a joint statement.

Roche s antibody cocktail to treat COVID-19 now available in India

Roche’s antibody cocktail to treat COVID-19 now available in India Roche’s antibody cocktail to treat COVID-19 now available in India 24 May 2021 | News Cipla to market the drug pan-India Roche India and Cipla have announced that the first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 200,000 patients as each of the 100,000 packs that will be available in India offers treatment for two patients. Cipla will distribute the product by leveraging its strong distribution strengths across the country. The drug will be available through leading hospitals and COVID treatment centres.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.